Please assess the completion status of the following clinical trial:

Trial Title: Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Diagnosed with FAB subtypes RA, RARS MDS (Low Risk)~OR~Diagnosed with AML and in complete remission within 5 years of treatment with less than 5 percent marrow blasts~OR~Diagnosed with CML In chronic phase~OR~Diagnosed with MDS, AML or CML and are between 6 months-3 years following allogeneic SCT who fulfill the following criteria:~100 percent donor engraftment,~less than 5 percent blasts in marrow~normal marrow cellularity~HLA-A0201 positive at one allele~Ages 18 - 85 years old~EXCLUSION CRITERIA:~Hypoplastic MDS~Relapsed AML~CML in accelerated phase or blast crisis~Relapsed MDS, AML or CML following hematopoietic stem cell transplantation~Hb less than 9 g/dl, neutrophil count less than 1 times 10(9)/1, and/ or platelet count less than 75 times 10(9)/1~Hypocellular bone marrow~History of Wegener's granulomatosis~Serologic antibody against proteinase-3 (ANCA positive)~Previous allergic reaction to montanide adjuvant~Positive test for HIV~Treatment with systemic corticosteroids within 14 days prior to study entry~Co-morbidity of such severity that it would preclude the subject's ability to tolerate protocol therapy~Predicted survival less than 28 days~Pregnant or breast feeding (All female subjects must have a urine pregnancy test within 1 week prior to vaccine administration)~Enrolled in another drug or vaccine clinical trial during the study period~Inability to comprehend the investigational nature of the study and provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).